Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients

Table 2 Health Care Claims of Individuals with JIA during transfer

	Pediatric Interval	Transfer Interval	Adult Interval	p value
MTX PO	10 (17.24 %)	9 (15.52 %)	11 (18.97 %)	0.8
MTX SQ	4 (6.90 %)	3 (5.17 %)	1 (1.72 %)	0.1
TNFi	19 (32.76 %)	14 (24.14 %)	24 (41.38 %)	0.2
GC	16 (27.59 %)	18 (31.03 %)	16 (27.59 %)	1
OP	16 (27.59 %)	12 (20.69 %)	17 (29.31 %)	0.8
NSAID	25 (43.10 %)	21 (36.21 %)	17 (29.31 %)	0.06
ER	11 (18.97 %)	11 (18.97 %)	12 (20.69 %)	0.8
PT	14 (24.14 %)	10 (17.24 %)	11 (18.97 %)	0.4
Physician diagnosis codes
JRA (714.3x)	41 (70.69 %)		16 (27.59 %)	<0.0001
Psoriatic arthritis (696.0)	3 (5.17 %)		3 (5.17 %)	1
Spondyloarthritis (720.xx)	16 (27.59 %)		14 (24.14 %)	0.3
RA (714.0)	0 (0 %)		26 (44.83 %)

Number of individuals who received medications, had ≥ PT visit, ≥ 1 ER visit, and physician diagnosis codes (not mutually exclusive) during each interval, n (%). The pediatric interval and adult interval proportions were compared by McNemar’s test with resulting p value
Abbreviations: MTX methotrexate, PO oral, SQ subcutaneous, TNFi tumor necrosis factor inhibitor, GC glucocorticoids, OP opiates, ER Emergency Room, PT physical therapy, JRA Juvenile Rheumatoid Arthritis, RA rheumatoid arthritis

ISSN: 1546-0096